A LinkedIn post from Databricks highlights how Real Chemistry is using Databricks Apps to deploy artificial intelligence models that identify undiagnosed rare-disease patients and analyze patient journeys. The post suggests that non-technical analysts at Real Chemistry can now access these capabilities without recurring engineering involvement.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Real Chemistry previously required six months to a year to build custom applications, whereas proofs of concept now reportedly launch within a week. The post also notes that more than 200 users across the organization are using self-service AI workflows, which may indicate growing adoption of Databricks’ platform in healthcare-focused analytics.
For investors, this use case may underscore Databricks’ value proposition in enabling faster time-to-insight and broader user access for enterprise AI workloads. The example from Real Chemistry could signal incremental demand from life-science and healthcare clients, potentially supporting Databricks’ competitive position in data and AI infrastructure as organizations seek scalable tools for specialized analytics.